InforMatrix^®: treatment of rheumatoid arthritis using biologicals

Bibliography

• LAGRO HAHM, VAN DEN BOSCH WJHM, BOHNEN AM et al.: NHG-Standard Rheumatoid Arthritis (first amendment). Family Physician Act. (2002) 45:534-543.
   Google Scholar
• KVIEN TK: Epidemiology and burden of illness of rheumatoid arthrithis. Pharmacoeconomics (2004) 22(2 Suppl.):1-12.
   PubMed Web of Science ®Google Scholar
• BIJLSMA JWJ, VOORN TB (Eds): Rheumatology. Bohn Stafleu Van Loghum, Houten/Diegem 2000.
   Google Scholar
• Classification of rheumatoid arthritis. Arthritis Rheum. (1988) 31:315-324.
   PubMed Web of Science ®Google Scholar
• VAN LEEUWEN MA, VAN RIJSWIJK MH: New criteria of the American Rheumatism Association for the classification of rheumatoid arthritis. Ned. Tijdschr. Geneeskd (1990) 134:420-422.
   PubMedGoogle Scholar
• Slow-acting anti-rheumatics. Geneesmiddelenbull (2001) 35:59-65.
   Google Scholar
• Guidelines for the management of rheumatoid arthritis. Arthritis Rheum. (1996) 39:713-722.
   PubMedGoogle Scholar
• EGSMOSE C, LUND B, BORG G et al.: Patients with rheumatoid arthritis benefit from early 2nd line therapy: 5 year followup of a prospective double blind placebo controlled study. J. Rheumatol. (1995) 22:2208-2213.
   PubMed Web of Science ®Google Scholar
• VAN LOENEN A: Farmacotherapeutisch Kompas (2006).
   Google Scholar
• BREEDVELD FC, ALBADA-KUIPERS GA, VAN DEN HOOGEN FHJ: Guideline: The application of TNF-block in the treatment of rheumatoid arthritis: Ned Tijdschr Reumatologie (2004):11-12.
   Google Scholar
• BATHON JM, MARTIN RW, FLEISCHMANN RM et al.: A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N. Engl. J. Med. (2000) 343:1586-1593.
   PubMed Web of Science ®Google Scholar
• ST CLAIR EW, VAN DER HEIJDE DM, SMOLEN JS et al.: Active-Controlled Study of Patients Receiving Infliximab for the Treatment of Rheumatoid Arthritis of Early Onset Study Group. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum. (2004) 50:3432-3443.
   PubMed Web of Science ®Google Scholar
• QUINN MA, CONAGHAN PG, O’CONNOR PJ et al.: Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. Arthritis Rheum. (2005) 52:27-35.
   PubMed Web of Science ®Google Scholar
• FELSON DT, ANDERSON JJ, BOERS M et al.: The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. (1993) 36:729-740.
   PubMed Web of Science ®Google Scholar
• FELSON DT, ANDERSON JJ, BOERS M et al.: American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum. (1995) 38:727-735.
   PubMed Web of Science ®Google Scholar
• VAN DER HEIJDE DM, VAN RIEL PL, NUVER-ZWART IH et al.: Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis. Lancet (1989) 1:1036-1038.
   PubMedGoogle Scholar
• FRIES JF, SPITZ PW, YOUNG DY: The dimensions of health outcomes: the Health Assessment Questionnaire, disability and pain scales. J. Rheumatol. (1982) 9:789-793.
   PubMed Web of Science ®Google Scholar
• ELLIOTT MJ, MAINI RN, FELDMANN J et al.: Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis. Lancet (1994) 344:1125-1127.
   PubMed Web of Science ®Google Scholar
• KAVANAUGH A, ST CLAIR W, MCCUNE J et al.: Chimeric anti-tumor necrosis factor-α monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. J. Rheumatol. (2000) 27:841-850.
   PubMed Web of Science ®Google Scholar
• MAINI SR: Infliximab treatment of rheumatoid arthritis. Rheum. Dis. Clin. North Am. (2004) 30:329-347.
   PubMed Web of Science ®Google Scholar
• MAINI R, ST CLAIR EW, BREEDVELD F et al.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised Phase III trial. ATTRACT Study Group. Lancet (1999) 354:1932-1939.
   PubMed Web of Science ®Google Scholar
• LIPSKY PE, VAN DER HEIJDE DM, ST CLAIR EW et al.: Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N. Engl. J. Med. (2000) 343:1594-1602.
   PubMed Web of Science ®Google Scholar
• BREEDVELD FC, EMERY P, KEYSTONE E et al.: Infliximab in active early rheumatoid arthritis. Ann. Rheum. Dis. (2004) 63:149-155.
   PubMed Web of Science ®Google Scholar
• KEYSTONE EC, HARAOUI B, BYKERK VP: Role of infliximab in the treatment of early rheumatoid arthritis. Clin. Exp. Rheumatol. (2003) 21(Suppl. 31):S200-S202.
   Web of Science ®Google Scholar
• TAYLOR PC, STEUER A, GRUBER J et al.: Comparison of ultrasonographic assessment of synovitis and joint vascularity with radiographic evaluation in a randomized, placebo-controlled study of infliximab therapy in early rheumatoid arthritis. Arthritis Rheum. (2004) 50:1107-1116.
   PubMed Web of Science ®Google Scholar
• MAINI RN, BREEDVELD FC, KALDEN JR et al.: Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum. (1998) 41:1552-1563.
   PubMed Web of Science ®Google Scholar
• GENOVESE MC, BATHON JM, MARTIN RW et al.: Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. (2002) 46:1443-1450.
   PubMed Web of Science ®Google Scholar
• KEYSTONE EC, SCHIFF MH, KREMER JM et al.: Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. (2004) 50:353-363.
   PubMed Web of Science ®Google Scholar
• KLARESKOG L, VAN DER HEIJDE D, DE JAGER JP et al.: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. Lancet (2004) 363:675-681.
   PubMed Web of Science ®Google Scholar
• WEINBLATT ME, KREMER JM, BANKHURST AD et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N. Engl. J. Med. (1999) 340:253-259.
   PubMed Web of Science ®Google Scholar
• MORELAND LW, SCHIFF MH, BAUMGARTNER SW et al.: Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. Ann. Intern. Med. (1999) 130:478-486.
   PubMed Web of Science ®Google Scholar
• VAN DE PUTTE LB, RAU R, BREEDVELD FC et al.: Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, Phase II study. Ann. Rheum. Dis. (2003) 62:1168-1177.
   PubMed Web of Science ®Google Scholar
• DEN BROEDER A, VAN DE PUTTE L, RAU R et al.: A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. J. Rheumatol. (2002) 29:2288-2298.
   PubMed Web of Science ®Google Scholar
• VAN DE PUTTE LBA, ATKINS C, MALAISE M et al.: Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann. Rheum. Dis. (2004) 63:508-516.
   PubMed Web of Science ®Google Scholar
• KEYSTONE EC, KAVANAUGH AF, SHARP JT et al.: Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum. (2004) 50:1400-1411.
   PubMed Web of Science ®Google Scholar
• FURST DE, SCHIFF MH, FLEISCHMANN RM et al.: Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J. Rheumatol. (2003) 30:2563-2571.
   PubMed Web of Science ®Google Scholar
• WEINBLATT ME, KEYSTONE EC, FURST DE et al.: Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum. (2003) 48:35-45.
   PubMed Web of Science ®Google Scholar
• RAU R, SIMIANER S, VAN RIEL P et al.: Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate. Scand J. Rheumatol. (2004) 33:145-153.
   PubMed Web of Science ®Google Scholar
• BREEDVELD FC, WEISMAN MH, KAVANAUGH AF et al.: The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum. (2006) 54:26-37.
   PubMed Web of Science ®Google Scholar
• BRESNIHAN B, ALVARO-GRACIA J, COBBY M et al.: Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. (1998) 41:2196-2204.
   PubMed Web of Science ®Google Scholar
• COHEN S, HURD E, CUSH J et al.: Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum. (2002) 46:614-624.
   PubMed Web of Science ®Google Scholar
• COHEN SB, WOOLLEY JM, CHAN W et al.: Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis. J. Rheumatol. (2003) 30:225-231.
   PubMed Web of Science ®Google Scholar
• COHEN SB, MORELAND LW, CUSH JJ et al.: A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. Ann. Rheum. Dis. (2004) 63:1062-1068.
   PubMed Web of Science ®Google Scholar
• BRESNIHAN B, NEWMARK R, ROBBINS S et al.: Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial. J. Rheumatol. (2004) 31:1103-1111.
   PubMed Web of Science ®Google Scholar
• NUKI G, BRESNIHAN B, BEAR MB et al.: Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. (2002) 46:2838-2846.
   PubMed Web of Science ®Google Scholar
• FLENDRIE M, CREEMERS MCW, WELSING PMJ et al.: Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. Ann. Rheum. Dis. (2003) 62(Suppl. II):ii30-ii33
   PubMedGoogle Scholar
• GEBOREK P, CRNKIC M, PETERSSON IF et al.: Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann. Rheum. Dis. (2002) 61:793-798.
   PubMed Web of Science ®Google Scholar
• CIENTIFICO BIOBADASER C: Spanish experience with a registry of adverse events on biological therapy. Ann. Rheum. Dis. (2003) 61(Suppl. 1):S388.
   Google Scholar
• MAINI RN, BREEDVELD FC, KALDEN JR et al.: Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum. (2004) 50:1051-1065.
   PubMed Web of Science ®Google Scholar
• BAUMGARTNER SW, FLEISCHMANN RM, MORELAND LW et al.: Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability. J. Rheumatol. (2004) 31:1532-1537.
   PubMed Web of Science ®Google Scholar
• MATHIAS SD, COLWELL HH, MILLER DP et al.: Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. Clin. Ther. (2000) 22:128-139.
   PubMed Web of Science ®Google Scholar
• ELLIOTT MJ, MAINI RN, FELDMANN M et al.: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. Arthritis Rheum. (1993) 36:1681-1690.
   PubMed Web of Science ®Google Scholar
• HANSEN KE, HILDEBRAND JP, GENOVESE MC et al.: The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J. Rheumatol. (2004) 31:1098-1102.
   PubMed Web of Science ®Google Scholar
• YAZICI Y, ERKAN D: Do etanercept-naive patients with rheumatoid arthritis respond better to infliximab than patients for whom etanercept has failed? Ann. Rheum. Dis. (2004) 63:607-608.
   PubMed Web of Science ®Google Scholar
• VAN VOLLENHOVEN R, HARJU A, BRANNEMARK S et al.: Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. Ann. Rheum. Dis. (2003) 62:1195-1198.
   PubMed Web of Science ®Google Scholar
• HARAOUI B, KEYSTONE EC, THORNE JC et al.: Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J. Rheumatol. (2004) 31:2356-2359.
   PubMed Web of Science ®Google Scholar
• GOMEZ-PUERTA JA, SANMARTI R, RODRIGUEZ-CROS JR et al.: Etanercept is effective in patients with rheumatoid arthritis with no response to infliximab therapy. Ann. Rheum. Dis. (2004) 63:896.
   PubMed Web of Science ®Google Scholar
• NIKAS SN, VOULGARI PV, ALAMANOS Y et al.: The efficacy and safety of switching from infliximab to adalimumab. A comparative controlled study. Ann. Rheum. Dis. (2006) 65:257-260.
   PubMed Web of Science ®Google Scholar
• SALMON D: Recommendations about the prevention and management of tuberculosis in patients taking infliximab. Joint Bone Spine (2002) 69:170-172.
   PubMedGoogle Scholar
• BONGARTZ T, SUTTON AJ, SWEETING MJ et al.: Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA (2006) 295:2275-2285.
   PubMed Web of Science ®Google Scholar
• SCHEINFELD N: A comprehensive review and evaluation of the side effects of the tumor necrosis factor alpha blockers etanercept, infliximab and adalimumab. J. Dermatol. Treat. (2004) 15:280-294.
   PubMedGoogle Scholar
• MIKULS TR, MORELAND LW: TNF blockade in the treatment of rheumatoid arthritis: infliximab versus etanercept. Expert Opin. Pharmacother. (2001) 2:75-84.
   PubMedGoogle Scholar
• YAZICI Y, ERKAN D, PAGET SA: Monitoring by rheumatologists for methotrexate-, etanercept-, infliximab-, and anakinra-associated adverse events. Arthritis Rheum. (2003) 48:2769-2772.
   PubMedGoogle Scholar
• BANG LM, KEATING GM: Adalimumab: a review of its use in rheumatoid arthritis. BioDrugs (2004) 18:121-139.
   PubMed Web of Science ®Google Scholar
• KEYSTONE E, HARAOUI B: Adalimumab therapy in rheumatoid arthritis. Rheum. Dis. Clin. North Am. (2004) 30:349-364.
   PubMed Web of Science ®Google Scholar
• CULY CR, KEATING GM: Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. Drugs (2002) 62:2493-2537.
   PubMed Web of Science ®Google Scholar
• LASSOUED S, SIRE S, FARNY M et al.: Pulmonary aspergillosis in a patient with rheumatoid arthritis treated by etanercept. Clin. Exp. Rheumatol. (2004) 22:267-268.
   PubMedGoogle Scholar
• WARRIS A, BJORNEKLETT A, GAUSTAD P: Invasive pulmonary aspergillosis associated with infliximab therapy. N. Engl. J. Med. (2001) 344:1099-1100.
   PubMed Web of Science ®Google Scholar
• MOLLOY E, RAMAKRISHNAN S, MURPHY E et al.: Morbidity and mortality in rheumatoid patients during treatment with adalimumab and infliximab. Rheumatology (2004) 43:522-523.
   PubMedGoogle Scholar
• KEANE J, GERSHON S, WISE RP et al.: Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N. Engl. J. Med. (2001) 345:1098-1104.
   PubMed Web of Science ®Google Scholar
• CARMONA L, GOMEZ-REINO JJ, RODRIGUEZ-VALVERDE V et al.: Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. Arthritis Rheum. (2005) 52:1766-1772.
   PubMed Web of Science ®Google Scholar
• CUNNANE G, WARNOCK M, FYE KH et al.: Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis. Arthritis Rheum. (2002) 47:445-449.
   PubMed Web of Science ®Google Scholar
• SWALE VJ, PERRETT CM, DENTON CP et al.: Etanercept-induced systemic lupus erythematosus. Clin. Exp. Dermatol. (2003) 28:604-607.
   PubMed Web of Science ®Google Scholar
• ANKER SD, COATS AJ: How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH. Int. J. Cardiol. (2002) 86:123-130.
   PubMed Web of Science ®Google Scholar
• COLETTA AP, CLARK AL, BANARJEE P et al.: Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH. Eur. J. Heart. Fail. (2002) 4:559-661.
   PubMed Web of Science ®Google Scholar
• WOLFE F, MICHAUD K: Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. Am. J. Med. (2004) 116:305-311.
   PubMed Web of Science ®Google Scholar
• Heart failure on infliximab. Prescrire Int. (2002) 11:86-87.
   Google Scholar
• BREEDVELD FC, ALBADA-KUIPERS GA, VAN DEN HOOGEN FHJ: Guideline: the application of TNF-block in the treatment of rheuamtoid arthritis. Nederlands Tijdschrift voor Reumatologie (2004) 1.
   Google Scholar
• KEYSTONE EC: Advances in targeted therapy: safety of biological agents. Ann. Rheum. Dis. (2003) 62(Suppl. II):ii34-ii36.
   PubMedGoogle Scholar
• GEBOREK P, BLADSTROM A, TURESSON C et al.: Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann. Rheum. Dis. (2005) 64:699-703.
   PubMed Web of Science ®Google Scholar
• PATEL T, GORDON KB: Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis. Dermatol. Ther. (2004) 17:427-431.
   PubMedGoogle Scholar
• FLEISCHMANN R, STERN R, IQBAL I: Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis. Expert Opin. Biol. Ther. (2004) 4:1333-1344.
   PubMed Web of Science ®Google Scholar
• KEATING GM, PERRY CM: Infliximab: an updated review of its use in Crohn’s disease and rheumatoid arthritis. BioDrugs (2002) 16:111-148.
   PubMed Web of Science ®Google Scholar
• FLEISCHMANN R, IQBAL I, NANDESHWAR P et al.: Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept. Drug Saf. (2002) 25:173-197.
   PubMed Web of Science ®Google Scholar
• HARLEY CR, FRYTAK JR, TANDON N: Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. Am. J. Manag. Care (2003) 9(6 Suppl.):S136-143.
   PubMed Web of Science ®Google Scholar
• GENOVESE MC, COHEN S, MORELAND L et al.: Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. Arthritis Rheum. (2004) 50:1412-1419.
   PubMed Web of Science ®Google Scholar
• ZHOU H, PATAT A, PARKS V et al.: Absence of a pharmacokinetic interaction between etanercept and warfarin. J. Clin. Pharmacol. (2004) 44:543-550.
   PubMed Web of Science ®Google Scholar
• ZHOU H, MAYER PR, WAJDULA J et al.: Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. J. Clin. Pharmacol. (2004) 44:1235-1243.
   PubMed Web of Science ®Google Scholar
• ZHOU H, PARKS V, PATAT A, LE COZ F et al.: Absence of a clinically relevant interaction between etanercept and digoxin. J. Clin. Pharmacol. (2004) 44:1244-1251.
   PubMed Web of Science ®Google Scholar
• LYSENG-WILLIAMSON KA, FOSTER RH: Infliximab: a pharmacoeconomic review of its use in rheumatoid arthritis. Pharmacoeconomics (2004) 22:107-132.
   PubMed Web of Science ®Google Scholar
• KOBELT G, JONSSON L, YOUNG A et al.: The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. Rheumatology (2003) 42:326-335.
   PubMed Web of Science ®Google Scholar
• KOBELT G, EBERHARDT K, GEBOREK P: TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden. Ann. Rheum. Dis. (2004) 63:4-10.
   PubMed Web of Science ®Google Scholar
• BRENNAN A, BANSBACK N, REYNOLDS A et al.: Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK. Rheumatology (2004) 43:62-72.
   PubMed Web of Science ®Google Scholar
• LYSENG-WILLIAMSON KA, PLOSKER GL: Etanercept: a pharmacoeconomic review of its use in rheumatoid arthritis. Pharmacoeconomics (2004) 22:1071-1095.
   PubMedGoogle Scholar
• CUMMINS C, CONNOCK M, FRY-SMITH A et al.: A systematic review of effectiveness and economic evaluation of new drug treatments for juvenile idiopathic arthritis: etanercept. Health Technol. Assess. (2002) 6:1-43.
   PubMedGoogle Scholar
• JOBANPUTRA P, BARTON P, BRYAN S et al.: The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. Health Technol. Assess. (2002) 6:1-110.
   PubMedGoogle Scholar
• NUIJTEN MJ, ENGELFRIET P, DUIJN K et al.: A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis. Pharmacoeconomics (2001) 19:1051-1064.
   PubMed Web of Science ®Google Scholar